--- title: "Vosoritide | PepTracker Pro" url: https://peptrackerpro.com/peptides/vosoritide description: "A once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Vosoritide High Evidence A once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333. Aliases Voxzogo +6 more Evidence High Evidence Last Updated 2026-07-20 Reading Time 5 min ## What It Is Vosoritide (development code BMN 111; BioMarin Pharmaceutical) is a recombinant, chemically stabilized 39-amino-acid analog of human C-type natriuretic peptide (CNP). It is the first drug approved to treat the underlying growth failure of achondroplasia, the most common form of disproportionate short stature (skeletal dysplasia), which affects roughly 1 in 25,000 births. Achondroplasia is caused by a gain-of-function mutation in FGFR3 (fibroblast growth factor receptor 3); the mutant receptor is chronically overactive and puts a constant brake on the cartilage growth plates at the ends of long bones, so endochondral bone growth is stunted. CNP is the body's natural counter-signal: acting through its receptor NPR-B, it inhibits the MAPK (RAS/RAF/MEK/ERK) arm of FGFR3 signaling and promotes chondrocyte proliferation and differentiation. Native CNP is destroyed within seconds by the enzyme neutral endopeptidase (NEP/neprilysin), which makes it useless as a drug; vosoritide is engineered to resist that breakdown while retaining NPR-B binding, giving it a plasma half-life long enough for once-daily dosing. It is given as a daily subcutaneous injection, weight-based (about 15 micrograms per kilogram). In the pivotal placebo-controlled Phase 3 trial, vosoritide increased annualized growth velocity by about 1.57 cm/year versus placebo over 52 weeks, and long-term extension data have shown the effect is durable over multiple years. The FDA granted accelerated approval on November 19, 2021 for children 5 years and older with achondroplasia and open (unfused) growth plates, based on the improvement in growth velocity; in 2023 the approval was expanded to children under 5, so it now covers all ages with open growth plates, and international consensus guidelines recommend starting treatment as early as possible. Vosoritide is a physician-prescribed, manufactured biologic-class peptide - not a self-sourced 'research chemical.' In 2026, BioMarin presented new multi-year data (arm span, body proportionality, bone health) at the ACMG, Pediatric Endocrine Society and ENDO meetings, reported three-year results in the related condition hypochondroplasia to support a planned FDA submission, and shared early data on BMN 333, a long-acting CNP peptide designed for once-weekly dosing. Also known as: Voxzogo, BMN 111, BMN-111, modified CNP, CNP analog, C-type natriuretic peptide analog, vosoritide injection ## Regulatory Status FDA-approved (prescription) for achondroplasia in children with open growth plates Vosoritide (Voxzogo) received FDA accelerated approval on November 19, 2021 to increase linear growth in children aged 5 and older with achondroplasia and open epiphyses (growth plates). In 2023 the FDA expanded the indication to children under 5, so it now covers all pediatric patients with open growth plates. It is also approved in the EU and many other regions. It is a physician-prescribed injectable peptide, not a self-sourced research compound; any vendor selling 'vosoritide' or 'BMN 111' powder for self-use is illegitimate. Effective: July 2026 View FDA Source (https://www.drugs.com/history/voxzogo.html) ## Why Researchers Study It Vosoritide is the proof-of-concept that a rare skeletal disorder can be treated by pharmacologically restoring a peptide signal that the disease-causing mutation has drowned out. Rather than trying to block the mutant FGFR3 receptor directly, it supplies extra CNP tone through a parallel receptor (NPR-B) to counterbalance the overactive brake on the growth plate - an elegant example of 'signal-balancing' therapy. For peptide scientists it is a case study in drug-hunting engineering: native CNP is degraded in seconds by neprilysin, so the challenge was to stabilize a fragile 39-residue hormone enough for once-daily injection while preserving receptor binding and avoiding the blood-pressure effects of the broader natriuretic-peptide system. Its success has opened an entire pipeline of CNP-pathway agents - including long-acting analogs (BMN 333) and prodrug approaches (TransCon CNP / navepegritide) aimed at weekly dosing - and has spurred exploration of the same biology in related conditions such as hypochondroplasia and other FGFR3-driven or growth-plate disorders. ## Proposed Mechanisms - Recombinant 39-amino-acid analog of human C-type natriuretic peptide (CNP), engineered to resist degradation by neutral endopeptidase (NEP/neprilysin) for a once-daily dosing half-life - Binds natriuretic peptide receptor-B (NPR-B) on growth-plate chondrocytes, raising intracellular cGMP - Inhibits the MAPK (RAS/RAF/MEK/ERK1/2) arm of FGFR3 signaling - the pathway made overactive by the achondroplasia mutation - Relieves the excessive 'brake' on the growth plate, restoring chondrocyte proliferation, differentiation and endochondral ossification - Increases annualized linear growth velocity and, over years, cumulative height and improved body proportionality - Acts one step downstream of the mutant FGFR3 receptor rather than blocking it directly, a signal-balancing rather than receptor-blocking strategy ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | RCT (human, Phase 3 - pivotal) | Achondroplasia - 121 children aged 5-14, daily subcutaneous vosoritide 15 mcg/kg vs placebo over 52 weeks | Annualized growth velocity improved by ~1.57 cm/year in favor of vosoritide (1.40 cm/yr vs -0.17 cm/yr for placebo); basis for the 2021 accelerated approval | Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC12352272/ | | Long-term extension / real-world evidence | Achondroplasia - multi-year open-label extensions and registry/real-world cohorts (children of various ages, including under 5) | Sustained increase in growth velocity over multiple years with improvements in body proportionality and arm span; effect durable and generally consistent with the controlled trial | Source: https://www.biomarin.com/news/press-releases/biomarin-presents-new-data-on-the-effect-of-long-term-treatment-with-voxzogo-vosoritide-on-arm-span-bone-health-and-growth-in-children-with-achondroplasia-at-the-pediatric-endocrine-society/ | | Regulatory milestone | Achondroplasia (BioMarin) | FDA accelerated approval November 19, 2021 for children 5+ with open growth plates; indication expanded in 2023 to children under 5, covering all ages with open growth plates | Source: https://www.drugs.com/history/voxzogo.html | | Pipeline / mechanism extension (2026) | Hypochondroplasia (3-year data) and BMN 333, a long-acting CNP peptide for achondroplasia (early data, ENDO 2026) | Three-year hypochondroplasia data support a planned FDA submission; BMN 333 showed sustained systemic exposure and prolonged target engagement supporting a once-weekly dosing schedule | Source: https://www.biospace.com/press-releases/biomarin-announces-new-three-year-voxzogo-vosoritide-data-in-hypochondroplasia-and-bmn-333-early-results-at-endo-2026 | ## Commonly Discussed Benefits Bone Growth: https://peptrackerpro.com/benefits/bone-growth Researching Vosoritide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=vosoritide) ## Safety & Cautions - Approved only for children with achondroplasia who still have OPEN growth plates; it has no growth benefit once the plates have fused and is not a general-purpose 'height' or performance drug - A physician-prescribed injectable biologic given under specialist (pediatric endocrinology/genetics) supervision - not a self-administered 'research peptide.' Any vendor selling 'vosoritide' or 'BMN 111' powder is illegitimate and unsafe - The most clinically watched risk relates to its natriuretic-peptide origin: transient decreases in blood pressure. Trials used strategies (adequate food/fluid intake before dosing) to mitigate symptomatic hypotension, and low blood pressure is a labeled warning - Common adverse events include injection-site reactions and, less often, symptoms of low blood pressure (dizziness, fatigue, nausea); ongoing monitoring of growth, blood pressure and bone health is required - Approved under the FDA's accelerated pathway based on growth velocity; long-term outcomes such as effects on final adult height, spinal/foramen magnum complications and function are still being characterized in extension studies - Not medical advice. Dosing, eligibility and monitoring are individualized decisions made by a qualified clinician ## Comparisons See how Vosoritide compares to related peptides: Vosoritide vs Abaloparatide: https://peptrackerpro.com/compare/vosoritide-vs-abaloparatide Vosoritide vs Navepegritide: https://peptrackerpro.com/compare/vosoritide-vs-navepegritide Vosoritide vs Palopegteriparatide: https://peptrackerpro.com/compare/vosoritide-vs-palopegteriparatide Vosoritide vs Sermorelin: https://peptrackerpro.com/compare/vosoritide-vs-sermorelin Vosoritide vs Setmelanotide: https://peptrackerpro.com/compare/vosoritide-vs-setmelanotide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Voxzogo (vosoritide) FDA Approval History - Drugs.com PubMed (https://www.drugs.com/history/voxzogo.html) 2. [2] Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence - PMC PubMed (https://pmc.ncbi.nlm.nih.gov/articles/PMC12352272/) 3. [3] Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia - ACMG therapeutics bulletin (PMC) PubMed (https://pmc.ncbi.nlm.nih.gov/articles/PMC11613676/) 4. [4] BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 - BioSpace PubMed (https://www.biospace.com/press-releases/biomarin-announces-new-three-year-voxzogo-vosoritide-data-in-hypochondroplasia-and-bmn-333-early-results-at-endo-2026) 5. [5] VOXZOGO (vosoritide) for injection - FDA prescribing information (label) PubMed (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214938s004lbl.pdf) ### Keep researching in the app - Log Vosoritide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=vosoritide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Abaloparatide High Evidence Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label. Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Hormone Support (https://peptrackerpro.com/benefits/hormone-support)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/abaloparatide \+ Compare: https://peptrackerpro.com/compare?select=abaloparatide Track in App: https://app.peptrackerpro.com/?add=abaloparatide ### Navepegritide High Evidence A C-type natriuretic peptide (CNP) analog FDA-approved in February 2026 for increasing linear growth in children with achondroplasia — the first once-weekly CNP therapy. Joint Health: https://peptrackerpro.com/benefits/joint-health Hormone Support: https://peptrackerpro.com/benefits/hormone-support View Details: https://peptrackerpro.com/peptides/navepegritide \+ Compare: https://peptrackerpro.com/compare?select=navepegritide Track in App: https://app.peptrackerpro.com/?add=navepegritide ### Palopegteriparatide High Evidence Palopegteriparatide (Yorvipath, developed as TransCon PTH) is Ascendis Pharma's once-daily prodrug of parathyroid hormone (1-34). An inert methoxy-PEG carrier is attached to PTH(1-34) through a TransCon linker that auto-cleaves at physiologic pH and temperature, releasing unmodified native-sequence PTH slowly enough to hold hormone levels inside the physiologic range for a full 24 hours. It is the first therapy approved as a true hormone replacement for chronic hypoparathyroidism rather than as an add-on to calcium and active vitamin D: in the Phase 3 PaTHway trial 78.7% of treated adults met a composite endpoint of normal serum calcium plus independence from conventional therapy at week 26, versus 4.8% on placebo. The FDA approved Yorvipath on August 9, 2024. Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Hormone Support (https://peptrackerpro.com/benefits/hormone-support)Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/palopegteriparatide \+ Compare: https://peptrackerpro.com/compare?select=palopegteriparatide Track in App: https://app.peptrackerpro.com/?add=palopegteriparatide ### Sermorelin Medium Evidence A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment. Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Sleep (https://peptrackerpro.com/benefits/sleep)Recovery (https://peptrackerpro.com/benefits/recovery)+1 more View Details: https://peptrackerpro.com/peptides/sermorelin \+ Compare: https://peptrackerpro.com/compare?select=sermorelin Track in App: https://app.peptrackerpro.com/?add=sermorelin ### Setmelanotide High Evidence A once-daily subcutaneous cyclic octapeptide melanocortin-4 receptor (MC4R) agonist, FDA-approved for several rare genetic and acquired forms of obesity that act through the leptin-melanocortin pathway. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/setmelanotide \+ Compare: https://peptrackerpro.com/compare?select=setmelanotide Track in App: https://app.peptrackerpro.com/?add=setmelanotide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Vosoritide", "description": "A once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333.", "url": "https://peptrackerpro.com/peptides/vosoritide", "lastReviewed": "2026-07-20", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Vosoritide", "item": "https://peptrackerpro.com/peptides/vosoritide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Parents and clinicians of children with achondroplasia weighing the first disease-modifying growth therapy and how early to start it?", "acceptedAnswer": { "@type": "Answer", "text": "Vosoritide is a research peptide studied in preclinical models. A once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333." } }, { "@type": "Question", "name": "Researchers studying the CNP/NPR-B axis and FGFR3 biology as targets in skeletal dysplasias and related growth disorders (e.g., hypochondroplasia)?", "acceptedAnswer": { "@type": "Answer", "text": "Vosoritide is a research peptide studied in preclinical models. A once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333." } }, { "@type": "Question", "name": "Peptide scientists interested in how a neprilysin-labile 39-residue hormone was stabilized into a practical once-daily medicine, and how longer-acting successors (BMN 333, TransCon CNP) are being engineered?", "acceptedAnswer": { "@type": "Answer", "text": "Vosoritide is a research peptide studied in preclinical models. A once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333." } } ] } ] ```